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INTRODUCTION 
 
In the last two decades, the therapeutic outcomes of ovarian germ cell 
tumor patients have dramatically improved. Patients with ovarian germ 
cell tumors who are well staged and whose tumors were initially 
completely resected and received adjuvant chemotherapy are very often 
cured.1 Additionally, ovarian germ cell tumor survivors usually are 
young and potentially have many years of productive life, if successfully 
treated. Thus, quality of life issues of long-term survivorship are of great 
importance.  
 
Ovarian germ cell tumor survivors are a small and unique population of 
cancer survivors. Although ovarian germ cell tumors occur in older 
children and younger women, the greatest frequency for diagnosis is in 
the teens and twenties.2 Unlike the majority of cancers, germ cell tumors 
strike during transition from adolescence to adulthood, a time of unique 
challenges. As treatment begins, concerns related to physical 
functioning, body image, mood, sexuality, family and vocational pursuits 
quickly emerge. The young age of women and girls diagnosed with this 
cancer, coupled with the high survival rates, presents an obligation to 
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investigate the occurrence of possible long-term physical or 
psychological sequelae of the cancer itself or the mechanisms used to 
treat it. Research addressing quality of life issues in ovarian germ cell 
survivors is limited. Hence we would like to study the quality of life 
issues in this subset. 
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AIMS 
 
(1) To analyze the quality of life among Long- Term survivors of 
ovarian germ cell tumors. 
 
(2) To compare the quality of life between fertility preserved and 
unpreserved group. 
 
(3) To study the pregnancy outcome in the fertility preserved 
survivors. 
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REVIEW OF LITERATURE 
 
Ovarian germ cell tumors (OGCTs) are derived from primordial germ 
cells of the ovary. They may be benign or malignant. These tumors 
account for only about 5 percent of all malignant ovarian neoplasms. 
Malignant Ovarian germ cell tumors (MOGCTs) arise primarily in 
young women between 10 and 30 years of age; they represent 70 percent 
of ovarian tumors in this age group.3 
 
Clinical Presentation and Initial Evaluation 
 
Several large case series from the 1970s and 1980s provided a detailed 
description of the clinical presentation associated with MOGCT.3 These 
tumors occur principally in girls and young women, with a mean age in 
the teenage years. Presenting signs and symptoms include abdominal 
pain and a palpable pelvic-abdominal mass in approximately 85% of 
patients. Approximately 10% of patients will present with acute 
abdominal pain mimicking appendicitis, usually caused by rupture, 
hemorrhage, or torsion of the ovarian tumor. Less common signs and 
symptoms include abdominal distension(35%), fever(10%), and vaginal 
bleeding(10%). A small proportion of patients exhibit isosexual 
precocity related to human chorionic gonadotropin(hCG) production by 
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the tumor. Many of the OGCT produce serum tumor markers that can 
serve as an adjunct in initial diagnosis, monitoring during therapy, and 
post-treatment surveillance. Yolk sac tumor and choriocarcinoma are the 
prototypes of alpha-fetoprotein (AFP) and hCG production, respectively. 
Both embryonal carcinoma and polyembryoma may produce hCG and 
AFP, the former more commonly. A small percentage of dysgerminomas 
produce low levels of hCG related to the presence of multinucleated 
syncitiotrophoblastic giant cells, and approximately one third of 
immature teratomas produce AFP. Of course, mixed germ cell tumors 
may produce either, both, or none, depending on the type and quantity of 
elements present. Occasionally, other serum tumor markers, such as 
lactic dehydrogenase, may be elevated in patients with OGCT, 
particularly dysgerminoma. 
 
Initial evaluation of a patient with a suspected OGCT based on history 
and physical examination should include routine blood studies, serum 
tumor markers, chest x-ray, and imaging studies- pelvic sonography and 
computed tomography (CT) of the abdomen and pelvis. If dysgenetic 
gonads are suspected based on physical findings and a history of primary 
amenorrhea, then karyotyping is indicated. 
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Pathology 
 
Rare tumors, such as OGCTs, are quite difficult to study. One of the 
major factors contributing to this situation is the multiplicity of 
histologic patterns involved and the lack of uniformity in their 
nomenclature. Thanks to a generation of gynecologic pathologists who 
focused on these fascinating neoplasms- foremost among whom were 
Robert E. Scully, H. J. Norris, and Alexander Talerman- a useful 
classification system began to take shape in the 1970s and has been 
repeatedly refined to its current state as the 2003 WHO classification 
system.4 
 
Table 1. Classification of Malignant Ovarian Germ Cell Tumors 
 
I. Primitive germ cell tumors 
A. Dysgerminoma 
B. Yolk sac tumor 
1. Polyvesicular vitelline tumor 
2. Glandular variant 
3. Hepatoid variant 
C. Embryonal carcinoma 
D. Polyembryoma 
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E. Nongestational choriocarcinoma 
F. Mixed germ cell tumor, specify components 
II. Biphasic or triphasic teratoma 
G. Immature teratoma 
H. Mature teratoma 
1.Solid 
2.Cystic, dermoid cyst 
3.Fetiform teratoma, homunculus 
III. Monodermal teratoma and somatic-type tumors associated with 
biphasic or triphasic teratoma 
A. Thyroid tumor group 
B. Carcinoid group 
C. Neuroectodermal tumor group 
D. Carcinoma group 
E. Melanocytic group 
F. Sarcoma group 
G. Sebaceous tumor group 
H. Pituitary-type tumor group 
I. Retinal anlage tumor group 
J. Others 
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Practically, it is most useful to subdivide OGCT into dysgerminoma- the 
most common type and the counterpart of the male seminoma- and 
nondysgerminomatous tumors.  The most common types of 
nondysgerminomatous tumors are yolk sac tumor, immature teratoma, 
and mixed germ cell tumors, with embryonal carcinoma, nongestational 
choriocarcinoma, and polyembryoma being much less common. n the 
most recent version of the WHO classification system, OGCTs are 
divided into three categories: primitive germ cell tumors, biphasic or 
triphasic teratoma, and monodermal teratoma and somatic-type tumors 
associated with dermoid cysts. Among the recent advances in our 
understanding of the pathology of OGCTs are the enhanced recognition 
of the multiple variants of yolk sac tumor and the CNS tumor group, 
which can be divided into three distinct categories (differentiated, 
primitive, and anaplastic) and for which effective therapy appears to 
differ markedly from the more typical OGCT.5 
 
Prognostic factors 
 
Because of the extreme rarity of OGCT, identifying prognostic factors 
has been quite challenging. However, recent studies have confirmed long 
standing clinical impressions that the International Federation of 
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Gynecology and Obstetrics staging system’s (FIGO) stage, residual 
disease, histologic type, and elevation of serum tumor markers appear to 
be prognostic parameters for patients with OGCT.6 Lai et al6 found that 
advanced FIGO stage and nondysgerminoma/immature teratoma 
histology were associated with a significantly increased risk of treatment 
failure, and nondysgerminoma/immature teratoma and bulky residual 
disease after salvage surgery were significantly associated with a worse 
overall survival. Murugaesu et al7 reported that, in univariate and 
multivariate analyses, in addition to FIGO stage, elevation of both hCG 
and AFP but not when taken alone, was a strong predictor of survival. 
Neither study found that age at diagnosis was prognostic. 
 
Management Issues 
 
In general, the treatment principles for all types of malignant ovarian 
germ cell tumor are similar to those that guide the management of the 
more common epithelial ovarian cancer (EOC), with some exceptions: 
Surgery is required for diagnosis, staging, and treatment. As with EOC, 
the abdomen should be thoroughly explored, with complete surgical 
staging and optimal cytoreduction when safe and feasible. In contrast to 
EOC, most OGCTs are stage I at initial presentation, and most patients 
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can be safely treated with fertility-preserving surgery rather than total 
abdominal hysterectomy and bilateral salpingo-oophorectomy.  
 
Malignant OGCTs are highly sensitive to platinum-based chemotherapy. 
This fact, coupled with the poor outcomes from surgery alone (even for 
stage I disease), has led to routine administration of adjuvant cisplatin-
based chemotherapy to most patients except those with stage IA 
dysgerminoma and well-differentiated stage I immature teratoma.3 
 
In contrast to advanced EOC, women with advanced stage OGCTs can 
often be cured.3 
 
Fertility-preserving surgery 
 
Once the diagnosis of a malignant OGCT is confirmed by frozen section, 
removal of the uterus, both ovaries, and fallopian tubes is suggested for 
women who have completed childbearing. However, preservation of 
fertility is often desired since these tumors tend to occur in younger 
women. Unilateral salpingo-oophorectomy with preservation of a 
normal-appearing uterus and contralateral ovary is an appropriate 
procedure in such cases. Even after chemotherapy, at least 80 percent of 
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these women will resume normal menstrual function, and those who 
become pregnant appear to have no increase in pregnancy 
complications.8 
 
Late effects of chemotherapy  
 
Although there are substantial data regarding late effects of BEP in men 
with testicular cancer, sparse information is available for women with 
OGCTs. Among the long-term adverse events from chemotherapy 
reported in men who receive cisplatin-based chemotherapy are renal and 
gonadal dysfunction, neurotoxicity, cardiovascular toxicity, and 
secondary malignancies.  Bleomycin-induced pulmonary fibrosis is also 
rare but must be kept in mind, particularly if general anesthesia is 
needed. 
 
Gonadal function  
 
Although ovarian dysfunction or failure is a risk of platinum-based 
chemotherapy, most women who receive three or four courses of 
standard dose therapy will recover normal ovarian function, and 
childbearing is often preserved.9 In one representative series of 71 
patients treated with both fertility sparing surgery and combination 
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chemotherapy for germ cell malignancies, 62 (87 percent) resumed 
normal menstruation, and 24 of these women subsequently had 37 
offspring.10 Factors such as older age at initiation of chemotherapy, 
greater cumulative drug dose, and longer duration of therapy all have an 
adverse effect on future gonadal function.  
 
Secondary malignancies — An important cause of late morbidity and 
mortality in patients undergoing treatment for germ cell tumors is the 
development of secondary malignancies, both solid tumors and 
leukemia. Etoposide in particular has been implicated in the 
development of treatment-related leukemias. The chance of developing 
treatment-related leukemia following etoposide is dose-related. The 
incidence of leukemia is <0.5 percent in patients receiving a typical 
three- or four-cycle course of BEP, in which the cumulative etoposide 
dose is <2000 mg/m2, compared to as much as 5 percent ( representing a 
336-fold increase in the likelihood of leukemia) in those receiving more 
than 2000mg/m2.11 
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Young women’s concerns and quality of life(QOL) issues 
 
Psychological concerns 
 
Many women report perpetual sadness and depressive symptoms after 
they have been successfully treated for their cancer because of body 
image concerns, fear of recurrence and post-traumatic stress disorder.12 
Underlying psychiatric illnesses, both diagnosed and undiagnosed, 
combined with depressed moods, altered self-image and anxiety may 
also contribute to the development of female sexual dysfunction. 
Relationship dynamics can change once a woman has a cancer diagnosis. 
Other worries, which are independent of relationship status, include the 
threat of disease recurrence, early death, bodily disfigurement, weight 
changes, finances, employment and insurance.12 
 
Table 2. Variables associated with psychosocial adaptation12 
 
Social support 
 
Marital status 
Living arrangements 
Number of family members and relatives in vicinity 
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History 
Substance abuse 
Depression 
Mental health 
Major illness 
Current concerns 
Health  
Religion 
Work- finance 
Family 
Friends  
Self appraisal 
Others 
Education 
Employment 
Physical symptoms 
 
Ovarian germ cell tumor patients are usually treated successfully and 
little attention has been directed toward psychological distress that may 
result from the cancer experience. Thorne (2005) addressed the 
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prevalence of psychosocial distress in cancer patients and its resulting 
impact on both the patient’s QOL and the health care system which 
included increased use of health care at all levels.13 The more confidence 
a survivor has in her ability to communicate the better long-term QOL 
outcomes. Additionally, for most cancer patients, health care provider 
support is an important component of general support.  
 
A body of evidence is emerging that describes the impact of healthcare 
provider and patient communication on psychosocial distress in cancer 
survivors. As a result, several studies have directed interventions to 
increase communication and addressed both the provider and patient.14 
 
Fertility issues 
 
Before the 1980s, conventional wisdom held that chemotherapy 
treatment of a female patient in childhood, adolescence, or young 
adulthood almost invariably resulted in infertility. Factors such as 
cumulative drug dose, duration of therapy, and age at treatment were 
thought to be important in influencing the incidence of ovarian 
dysfunction.15 Several reports have documented successful pregnancies 
in young patients who previously underwent fertility-sparing surgery and 
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combination chemotherapy for malignant ovarian germ cell 
tumors.16,17,18-22 Gerhenson 23 reported a questionnaire study of 40 
patients treated for malignant ovarian germ cell tumors in which all 
patients were successfully treated with fertility-sparing surgery followed 
by combination chemotherapy; most patients received non-platinum 
based chemotherapy. At the time of analysis, 33 patients (83 %) were 
having regular menses. Premature menopause was documented in one 
patient. Of 16 patients who had attempted pregnancy since 
chemotherapy, 11 delivered 22 healthy infants, none of whom had major 
birth defects. 
 
Brewer17 et al reported their experience with 26 patients treated with 
surgery plus platinum-based chemotherapy for ovarian dysgerminoma. 
Of the patients who underwent fertility-sparing surgery and 
chemotherapy, 71 % maintained their normal menstrual function during 
and after chemotherapy, and 93% had returned to their prechemotherapy 
menstrual pattern at the time of the questionnaire. Three subsequent 
reports have detailed post-therapy reproductive function in patients with 
malignant ovarian germ cell tumors and have noted normal menstrual 
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function in at least 80%.24-26 Several live births were reported in each of 
these series. 
 
One of the strongest predictors of emotional well-being in cancer 
survivors, besides sexual function, appearance, and employability, is 
feeling healthy enough to be a good parent. Cancer survivors are often 
fearful that their history of cancer or its treatment will have an adverse 
impact on their offspring by placing them at risk for malignancy, 
congenital anomalies, or impaired growth and development. They are 
also concerned about the risks of cancer recurrence, infertility, 
miscarriage, and achieving a successful pregnancy outcome. 
 
Despite these concerns, surveys have reported that fewer than 60 percent 
of respondents had received information about fertility after cancer 
treatment, and even fewer had received information about potential risks 
to offspring.27 Others have reported that the rate of elective pregnancy 
termination among female cancer survivors was higher compared to 
sibling controls because of the fear that their prior cancer therapy would 
affect their children.28 Patient education regarding future reproductive 
function is thus an important component of the care of individuals with 
cancer.29 
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Spirituality 
 
One salient aspect of the distress of life threatening or terminal illness is 
spirituality. Smith and colleagues found that a higher level of spirituality 
is associated with an increase in the patient’s ability to normalize death. 
In a study of 116 medical oncology outpatients, a significant negative 
relationship was found between the interaction of spiritual awareness 
with the patient’s personal death perspective and psychosocial distress.30 
 
Cognitive- Behavioral interventions 
 
Patients frequently manifest a variety of symptoms as direct effects of 
cancer and its treatment. Most commonly identified symptoms include 
acute and chronic pain, anxiety, insomnia, hypochondriasis, anticipatory 
nausea and vomiting. A variety of cognitive and behavioral interventions 
can systematically be administered. 
 
Survivorship 
 
A number of studies indicate that while cancer survival may be achieved, 
it is still a disease that can substantially affect several physical and 
psychological aspects of a survivor’s life. Hypervigilance and 
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hypochondriasis are common reactions. They experience challenges in 
four critical life domains 
 
1 Physical health 
2 Psychological and social well being 
3 Maintaining adequate health insurance and 
4 Employment.31 
 
Physical health challenges include fear of recurrence, the possibility of 
second malignancy and other late effects of aggressive treatment. Many 
survivors actively meet these challenges through preventive regimes of 
diet, exercise, stress reduction and smoking cessation. In general, most 
survivors report mild to moderate psychological distress. Cancer 
Survivors often may be threatened by policy cancellations or reduction 
in coverage. Employment issues include failure to be promoted, negative 
attitude towards cancer and undue criticism from supervisors or co-
workers. 
 
Assessing quality of life 
 
Approximately 10% of all cancer clinical trials include health related 
QOL as one of the main end points.32 Quality of life is a subjective, 
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multidimensional concept reflecting the patient’s perception of all 
aspects of her health experience.  
 
The domains (areas of behavior or experience) include 
physical/functional (activity, appearance, appetite, condition, 
comorbidities, fatigue/sleep/rest disease stage/status genetics, symptoms, 
and side effects), demographics (age, ethnicity, education, employment, 
and income), spiritual (hope, meaning/purpose, religion, spirituality), 
social (family, life events, relationships, roles, sexuality, support), and 
psychological/cognitive factors (anxiety/fear, depression, body image, 
control, coping, enjoyment, optimism, perception and interpretation, and 
prior experience).33 QOL extends to include performance of everyday 
activities that reflect well-being, patient satisfaction, functioning and 
control of disease. Fears and hopelessness clearly play into how people 
cope with cancer, as do expectations, and the World Health Organization 
has broadened the definition of QOL to include the context of the 
culture, personal value systems, goals, standards, and concerns.34 
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QOL measurement in Gynecologic Oncology 
 
Quality of life measurement can provide information about the impact of 
the disease and its treatment on cancer patients to aid physicians in 
selecting both anti neoplastic and supportive-care therapy.  Several 
excellent instruments are available to measure health-related QOL in 
patients with gynecologic cancer. A typical approach combines a generic 
health status assessment such as the European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire(QLQ) QLQ-
C30,35 or the Functional Assessment of Cancer Therapy-General (FACT-
G),36 with a more targeted set of questions specific to a given tumor type.  
Basen-Engquist et al. validated a set of questions targeted to ovarian 
cancer which, when added to the FACT-G, is referred to as the FACT-
Ovarian (FACT-O) 12. FACT subscales for cervical and vulvar cancers 
are also available. The core questionnaire (FACT-G) primarily evaluates 
the patient’s physical, social/family, emotional, and functional 
wellbeing. The 13-item, ovarian cancer-specific subscale assesses 
severity of problems that can be addressed through proper disease 
management.37 The FACT-O can be used alone or in combination with 
other scales and subscales of the FACT, such as the FACT/GOG 
neurotoxicity subscale, if neurotoxicity is of concern, or the Anemia 
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subscale or Fatigue subscale if one is interested in these specific issues. 
Another recent addition to an ovarian disease-specific questionnaire 
module is the QLQ-OV28, developed to supplement the EORTC QLQ-
C30. This module incorporates numerous symptoms potentially 
encountered by ovarian cancer patients (e.g., abdominal, hormonal, 
sexual).38 Briefer instruments include the Spitzer and EQ-5D16, 17. Each 
of these measures provide QOL information relevant to a specific 
condition for which intervention could be useful, thus potentially 
improving total patient care. 
 
Clinical implications of QOL Measurement 
 
Managing QOL in gynecologic cancer patients requires careful 
consideration of all the domains that impact the patient: surgery, and the 
side effects of chemotherapy and radiotherapy, as well as disease-
associated factors that can negatively affect QOL. Prominent among the 
toxicities and symptoms that can diminish QOL in gynecologic cancer 
patients are pain, emotional distress, neuropathy, alopecia, nausea and 
vomiting, anemia, and fatigue.39 While some investigators remind us that 
it is impossible to measure a ‘sunbeam with a ruler’,40 the systematic 
development of validated instruments (measures) has allowed important 
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randomized clinical trials to report QOL. The evolving challenge is 
translating this advance from clinical trials into clinical practice. 
 
Conclusion 
 
Just as therapy for gynecologic cancer has developed into multimodality 
care, the impact that cancer treatment has on patients has widened. The 
gynecologic cancer patient faces many challenges specific to the type of 
tumor and its treatment, as well as those common to the general 
oncology population. Recent advances have both improved and 
challenged QOL. Evaluating and addressing QOL issues is an important 
part of the whole package of modern medical care. Caring for the 
patient, as well as her cancer, requires an evolving response and 
measures to preserve or enhance the quality as well as the quantity of 
life.  
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SUBJECTS AND METHODS 
 
Survivors of Germ cell Tumor Ovary, who had completed at least 2 
years of follow up after the completion of treatment were included in the 
study. (From 1995-2005) 
 
Inclusion criteria 
 
1. Pathology proven early or advanced malignant ovarian germ cell 
tumor. 
2. Survivors who were continuously disease-free with minimum 
follow up of two years at the time of the interview. 
 
Exclusion criteria 
 
1. Patients who had relapsed and received salvage therapy. 
2. Patients on palliative therapy. 
 
Methods 
 
Survivors of Ovarian Germ Cell Tumors from 1995-2005 were contacted 
over phone or letter to review at Out patient clinic. Quality of Life 
Questionnaire was administered after taking informed consent. 
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Questionnaire 
 
Two questionnaires were used namely EORTC QLQ-C30 and EORTC 
OV 28.  
 
Socio demographic variables included age at diagnosis, marital status, 
level of education and employment status. Medical variables included 
cancer stage, type of surgery, type of chemotherapy, ovarian function, 
and child birth after diagnosis. 
 
EORTC QLQ C30 and OV28 
 
The EORTC module QLQ-C30 is a 30 item questionnaire composed of 5 
multi item functional subscales : Physical health, role function, 
emotional function, cognitive function and social functioning; 3 multi 
item symptom scales measuring fatigue, pain and emesis; a global health 
scale and 6 items to assess financial impact and general symptoms. All 
of the scales and single-item measures range in score from 0 to 100. A 
high scale score represents a higher response level. Thus a high score for 
a functional scale represents a high/healthy level of functioning, a high 
score for the global health status/ QOL represents a high QOL, but a 
high score for a symptom scale/item represents a high level of 
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symptomatology/problems. EORTC QLQ- C30 has been validated in 
Indian patients.41 
 
The OV 28 module is designed for patients with local or advanced 
disease who receive treatment by surgery with or without chemotherapy. 
It was developed according to the EORTC guidelines. It consists of 28 
items assessing abdominal/Gastrointestinal symptoms, peripheral 
neuropathy, other chemotherapy side effects, hormonal symptoms, body 
image, attitudes to disease/treatment, and sexuality.  EORTC OV 28 
module as a supplement to EORTC QLQ C- 30 has been clinically and 
psychometrically validated.42 
 
Survivors completed the questionnaire on their own, however some of 
them required assistance. Only 7 survivors required assistance by 
translator and clinical psychologist as 3 were illiterates and the other 4 
did not know English. 
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Statistical Analysis 
 
Scoring of the QLQ-C30 and OV 28 was done according to the 
procedures described in the EORTC manual.35 Descriptive and 
Inferential statistics were used in order to analyze the data using SPSS 
version 13. 
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RESULTS 
 
Table 1 Age at Diagnosis 
 
Age ( years ) N=50 (%) 
1-10 4 (8%) 
11-20 21 (42%) 
21-30 22 (44%) 
31-40 2 (4%) 
41-50 1 (2%) 
 
Table 2 Educational Status 
 
Educational Status N=50 
Illiterate 3 (6%) 
Primary School 4 (8%) 
Secondary School 22 (44%) 
Graduation 18 (36%) 
Post graduation 3 (6%) 
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Table 3 Marital Status  
 
At Diagnosis Current Status 
 Single Married Widow Divorce 
Single (N=24) 21 3 0 0 
Married(N=24) 0 24 0 0 
Widow(N=2) 0 0 2 0 
Divorce(N=0) 0 0 0 0 
 
Table 4 Stage at diagnosis 
 
Stage N=50 (%) 
Stage I 22 (44%) 
Stage II 3 (6 %) 
Stage III 24 (48%) 
Staging not possible 1 (2%) 
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Table 5 Ovary Status 
 
Ovary Status N=50 (%) 
Ovary Preserved 28 (56%) 
Ovaries Removed 22 (44%) 
 
 
Table 6 Menstruation Status 
 
Menstruation Status N=50(%) 
Regained Menstruation 28(56%) 
No Menstruation 22(44%) 
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Table 7   Stage and Total Quality of Life 
 
Stage N Mean SD P value 
I & II 25 90.3316 12.19279 
0.107 
III 24 79.1638 20.99710 
All stages* 50 84.7456 16.32965  
 
* Staging was not possible in 1 patient 
SD – Standard Deviation 
 
Table 8   Ovary Status and Total Quality Of Life 
 
Ovary Status N Mean SD P value 
Preserved 28 90.4746 15.33648 
0.577 
Removed 22 77.6482 18.07414 
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Table 9 Difference in the different dimensions of QOL among early 
and advance stage survivors ( EORTC QLQ C-30 )  
 
Dimensions Stage N Mean 
Standard. 
Deviation 
P value 
Physical 
functioning 
I & II 25 94.4040 11.81064 
0.242 
III 24 91.9483 17.69026 
Role 
functioning 
I & II 25 96.9992 9.28158 
0.384 
III 24 95.8325 11.26332 
Emotional 
functioning 
I & II 25 90.4628 15.18585 
0.270 
III 24 87.2896 19.60309 
Cognitive 
functioning 
I & II 25 94.6632 17.67082 
0.315 
III 24 96.8742 9.45968 
Social 
functioning 
I & II 25 93.9992 19.02238 
0.418 
III 24 90.5100 20.01691 
Financial 
difficulties 
I & II 25 3.9996 14.65510 
0.004 
III 24 12.4713 25.59279 
Global health 
status 
I & II 25 90.3316 12.19279 
0.107 
III 24 79.1638 20.99710 
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Table 10 Difference in the different dimensions of QOL depending 
on the ovary status ( EORTC QLQ C-30 ) 
 
Dimensions Ovary Status N Mean Standard. 
Deviation 
P 
value 
Physical 
functioning 
Preserved 28 95.7179 10.91591 
0.04 
Removed 22 90.3073 18.37023 
Role 
functioning 
Preserved 28 98.5114 6.43793 
0.001 
Removed 22 93.9382 13.16167 
Emotional 
functioning 
Preserved 28 91.1271 13.83132 
0.027 
Removed 22 86.5891 20.92845 
Cognitive 
functioning 
Preserved 28 95.2350 16.74480 
0.510 
Removed 22 96.5900 9.84849 
Social 
functioning 
Preserved 28 97.3207 9.63725 
0.517 
Removed 22 86.2382 25.89951 
Financial 
difficulties 
Preserved 28 3.5711 13.87427 
0.001 
Removed 22 13.6050 26.48040 
Global health 
status 
Preserved 28 90.4746 15.33648 
0.577 
Removed 22 77.6482 18.07414 
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Table 11 Difference in the Symptom scales among early and advance 
stage survivors ( EORTC QLQ-OV28 ) 
 
Symptom scale Stage N Mean 
Standard. 
Deviation 
P value
Abdominal/GI I & II 25 3.3320 6.80210 
0.640 
III 24 3.9342 9.75677 
Peripheral neuropathy I & II 25 5.9996 17.26577 
0.499 
III 24 4.8600 14.30924 
Hormonal I & II 25 3.3324 8.33150 
0.005 
III 24 10.4154 16.15955 
Body image I & II 25 4.6660 12.28432 
0.429 
III 24 6.9429 12.92414 
Attitude to 
disease/treatment 
I & II 25 17.9972 22.40596 
0.854 
III 24 23.6075 22.05275 
Chemotherapy side 
effects 
I & II 25 6.9324 12.97771 
0.521 
III 24 5.9846 12.14468 
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Table 12 Difference in the Symptom scales depending on the ovary 
status ( EORTC QLQ-OV28 ) 
 
Symptom scale Stage N Mean 
Standard. 
Deviation 
P 
value
Abdominal/GI Preserved 28 2.5782 5.94769 
0.093
Removed 22 4.7968 10.46874 
Peripheral 
neuropathy 
Preserved 28 5.3568 16.38764 
0.806
Removed 22 5.3018 14.89298 
Hormonal Preserved 28 1.7850 5.24741 
0.005
Removed 22 14.3923 17.28515 
Body image Preserved 28 4.1661 11.67464 
0.205
Removed 22 7.5741 13.33916 
Attitude to 
disease/treatment 
Preserved 28 16.8625 21.66942 
0.870
Removed 22 24.7436 22.46459 
Chemotherapy side 
effects 
Preserved 28 5.4754 12.17789 
0.726
Removed 22 7.7405 12.68321 
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Table 13 Successful Pregnancies following treatment 
 
Sl. No 
Marital status 
before Rx 
Number Of 
Children Duration after 
treatment (years) Before 
Rx 
After 
Rx 
12 Married 1 1 4 
17 Married 1 1 3 
18 Single 0 1 11 
33 Married 0 1 5 
39 Married 0 2 2 & 5 
44 Married 0 1 1 ½ 
47 Married 0 1 2 
49 Married 0 1 2 
50 Single 0 2 1 & 4 
 
Rx- Treatment 
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Table 14 comparison of Physical functioning and Global health 
status in OGCT survivors 
 
Scale Referenced43 Referenced44 Survivors* 
 Mean SD Mean SD Mean SD 
Physical Functioning 83.65 32.21 78.47 35.77 93.05 18.37
Global Health 74.25 19.44 72.45 21.43 84.74 16.32
 
* Our Study 
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RESULTS 
 
100 survivors of Ovarian germ cell tumor treated between 1995 and 
2005 were contacted over phone or letter for QOL assessment at out 
patient clinic. 50 survivors, who had completed minimum 2 years of 
follow up turned up and were administered the questionnaire after 
obtaining informed consent. 
 
Demographic Profile 
 
Age at Diagnosis  (Table 1). 
 
The mean age at diagnosis was 20.16 years (7- 43 years) with 44 % of 
the patients between the age group of 21-30 years  
 
The mean age at the time of quality of life analysis was 27.46 years (15-
47 years) 
 
Education Status (Table 2) 
 
18 (36%) survivors were pursuing or completed their graduation, 3 were 
pursuing post graduate education. 4 stopped at primary education level, 
while only 3 were illiterates. 
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Marital Status (Table 3) 
 
24 patients were married at the time of diagnosis. Of the 24 unmarried, 3 
got married during follow up. 2 were widows at the time of diagnosis. 
There were no divorces.  
 
Stage and Treatment (Table 4) 
 
50% of the patients had early stage disease, while 48 % had advanced 
stage. Only 1 patient could not be staged. All except one patient received 
chemotherapy. Chemotherapy consisted of 3-4 cycles of Bleomycin, 
Etoposide, Cisplatin ( BEP ) 
 
Fertility Preservation and Menstrual Status (Tables 5 & 6) 
 
Fertility preservation surgery was possible in 28 patients (56%). All the 
28 patients regained their menstrual cycles. Among the 22 in whom 
contralateral ovary and fertility preservation was not possible, 7 were 
unmarried with mean age of 26.6 years (18-39 years). Among the ovary 
preserved group, 15 are still unmarried with mean age of 23 years (15- 
29 years).   
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Stage and Total QOL (Table 7) 
 
Total QOL scores were high in both early and advance stage survivors 
with a mean score of 90.33and 79.16 respectively. Mean score in all the 
survivors was 84.74. 
 
Ovary Status & Total Quality Of Life (Table 8) 
 
Total QOL score was not statistically significant among fertility 
preserved and unpreserved group. Both had high scores with a mean of 
90.47 and 77.65 respectively.  
 
Difference in different dimensions of quality of life issues (Tables 9 
and 10) 
 
There were no statistically significant different scores among early and 
advance stage survivors except for financial difficulties which was 
significantly more in advance stage survivors. Physical functioning, role 
functioning and emotional functioning were significantly better in the 
fertility preserved group.  
 
 
 
 
 
  
41
Difference in symptom scales (Tables 11 and 12) 
 
Hormonal symptoms were significantly more in advance stage survivors 
and the ovaries removed group.  
 
Fertility Issues (Table 13) 
 
There were 11 successful deliveries among 9 survivors, with a mean of 
3.5 years following completion of treatment. 2 survivors are on treatment 
for infertility and 15 are still unmarried among the fertility preserved 
group.  
 
Comparison with published data (Table14) 
 
Means and Standard deviation of QOL outcome variables are 
comparable with the published data. 
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DISCUSSION 
 
Ovarian germ cell tumors occur predominantly in the teens and twenties. 
Majority of them are unmarried or are planning their families. Most of 
them are educated and have many years of productive life. The purpose 
of this study was to determine what variables are most closely associated 
with quality of life outcomes in long-term survivors of ovarian germ cell 
tumor and also the impact of fertility preservation treatment. 
 
Impact of GCT Ovary on the demographic profile 
 
There was no effect of cancer diagnosis and treatment on the educational 
status. 2 completed graduation and took up job as teachers and 3 are 
pursuing post graduate course at the time of administering the 
questionnaire. Education level was high with 42% having a graduate 
degree. Only 14% had less than secondary school education. A large 
study by Victoria Champion et al44 also noted high education level in 
Ovarian GCT survivors. Educational level was high, with 47% having a 
college degree or some graduate school, 29% having some college, and 
21% being a high school graduate. Only 3% had less than a high school 
education in their study. 
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3 survivors have got married after the completion of treatment. However, 
a matter of concern was, 7 unmarried patients could not have their ovary 
preserved and continue to be unmarried.  The relatively high percentage 
of unmarried survivors may be related to survivor age, since more than 
40% are less than 25 years old. Marital status could also reflect the lower 
intimacy motivation which Cella and Tross45 reported in Hodgkin’s 
disease survivors, which may be related to lower marriage rates and 
higher divorce rates. This is not the case in our series as all the 
unmarried survivors are still young and are pursuing education. There 
were no divorces.  
 
Impact of treatment on quality of life 
 
Although there are substantial data regarding late effects of BEP in men 
with testicular cancer, sparse information is available for women with 
Ovarian Germ cell tumors. There were no significant long term treatment 
related side effects viz., pulmonary toxicity, neuropathy and deafness. 
Many currently used chemotherapeutic agents can induce significant 
toxicities, some cumulative or irreversible, that can potentially diminish 
QOL. Lower education, more menstrual/gynecological symptoms, and 
presence of cisplatin and bleomycin in the chemotherapy regimen were 
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significantly associated with greater (worse) neurotoxicity in a study by 
Victoria Champion et al.44A study by National Cancer Institute is 
currently recruiting survivors to assess the treatment outcome and quality 
of life in patients with Pediatric Extra-Cranial Germ Cell Tumors 
Previously Treated on Clinical Trial CCLG-GC-1979-01 or CCLG-GC-
1989-01 (NCT00436774).  
 
Impact of stage on Quality of Life score 
 
Both early and advanced stage patients had a high score in total quality 
of life score. The mean total QOL score was 84.74, which corresponded 
to high score according to the EORTC questionnaire.35 Physical 
functioning, role functioning and emotional functioning were 
significantly better in in the ovary preserved group. 
 
Hormonal symptoms such as hot flashes and vaginal dryness were 
significantly more in advance stage survivors. This could be due to 
bilateral ovariectomy as evident by the same trend in ovaries removed 
group. There are no studies comparing the QOL issues among early and 
advance stage survivors of OGCTs. Larger studies with more statistical 
power are required to confirm our findings.  
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Financial difficulties were significantly more in advance stage survivors. 
This could not be further qualified as most of the survivors were from 
low socioeconomic strata and requires a separate study addressing the 
social and economic issues. 
 
Means and standard deviations of QOL outcome variables were 
compared with published data. Scores for this sample were very similar 
to reports from other populations.43,44 Therefore it is evident that overall, 
the ovarian germ cell population was similar to other populations 
reported in the literature. 
 
Impact of Fertility Preservation 
 
Fertility preserved group had a significantly better general well being 
and body image. Physical functioning, role functioning and emotional 
functioning were significantly better in the fertility preserved group. 
 
Hormonal symptoms were significantly more in the ovaries removed 
group. There were no differences in other variables such as emotional 
functioning, cognitive functioning and social functioning. There were no 
differences in the symptom scale among two groups. There are no 
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studies comparing quality of life issues among ovary preserved and 
ovaries removed group.  
 
One aspect of quality of life for cancer survivors is the preservation of 
reproductive-endocrine function and fertility. The specific effects of 
cancer therapy on reproductive function are not as well understood, and 
there is no test for fertility except for a resulting pregnancy proving that 
fertility is maintained. 
 
In our study, all 28 patients who had their fertility preserved had 
recovery of menstruation. Some authors 23,46,47 observed that 20-30% of 
patients with malignant ovarian germ cell tumors  treated with both 
surgery and chemotherapy had disturbed menstrual function, whereas 
other authors published rates around 10%.49 
 
Gerhenson et al23. reported on 40 patients with OGCTs treated 
conservatively, where 68% of the women after completion of 
chemotherapy maintained regular menses, and 83 % of them were 
having regular menses at the time of the follow-up. Eleven women 
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delivered 22 healthy infants, none of whom presented major birth 
defects. 
 
In contrast to the data in the literature,10,17,23 100% survivors had regular 
menses at the time of interview.  
 
Among the 28 survivors who have undergone fertility sparing surgery, 
13 are married. 9 of them have had 11 successful pregnancies. None of 
them had any difficulty in conceiving, and there is no evidence of birth 
defects or other disabilities in any of the offspring. The mean duration of 
conception following completion of treatment was 3.5 years. 
 
In agreement with the rates reported in literature46,49  70% survivors have 
succeeded in conceiving.  Another encouraging observation is that 15 
(53.57%) are not yet married and are having regular menstrual cycles. 
The maintained reproductive potential is not the only issue involved in 
deciding whether to have children after cancer; other more complex 
psychological aspects could be involved in such an important decision. 
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Strengths of the study 
 
Duration of follow-up since chemotherapy is quite long (Mean 7 years) 
for the majority of survivors. 
 
An attempt to look into various dimensions of quality of life through 2 
questionnaires has been made. 
 
Detail analysis of successful pregnancies among fertility preserved group 
is provided.  
 
Comparison of Quality of life scores among early and advance stage 
survivors and among fertility preserved and ovariectomised group has 
been done, which is not reported in literature. 
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Limitations 
 
1. This was a cross-sectional survey. Our analyses were based on a 
theoretical model that specified direction, however, only a 
prospective study could determine if these findings are supported.  
 
2. It is possible that some associations mentioned in this study may have 
occurred by chance and are not reproducible. It is possible that 
unknown variables may have confounded results. 
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CONCLUSIONS 
 
1. The general psychological health and total quality of life is quite 
good for survivors of ovarian germ cell tumor survivors. 
 
2. Physical and emotional functioning were significantly better in 
fertility preserved group. 
 
3. Survivors who were rendered menopausal had more hormonal 
symptoms. 
 
4. The importance of fertility preservation is again emphasized and 
vigorous efforts to maintain reproductive potential during the initial 
surgical procedure continues to be warranted. 
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BACKGROUND QUESTIONNAIRE 
 
Name    : 
 
Age    : 
 
Out Patient No.  : 
 
Address   : 
 
 
 
Education   : 
 
Occupation   : 
 
Marital Status  : Single/ Married/ Divorced/ Widowed 
 
Number of children : 
 
Menstrual Cycle   : Present/Absent 
 
Date Of Diagnosis  : 
 
Histopathology  : 
 
Stage     : 
 
Treatment given  : 
 
Date of completion of  
Treatment   : 
 
Date of Interview  : 
 
Interviewer’s signature : 
 
